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Abstract: Anabolic androgenic steroids (AAS) are prohibited as doping substances in sports by the
World Anti-Doping Agency. Concentrations and concentration ratios of endogenous AAS (steroid
profile markers) in urine samples collected from athletes are used to detect their administration. Certain
(non-prohibited) drugs have been shown to influence the steroid profile and thereby sophisticate
anti-doping analysis. It was shown in vitro that the non-steroidal anti-inflammatory drug (NSAID)
indomethacin inhibits selected steroid-biotransformations catalyzed by the aldo-keto reductase
(AKR) 1C3, which plays a key role in the endogenous steroid metabolism. Kinetic parameters for
the indomethacin-mediated inhibition of the AKR1C3 catalyzed reduction in etiocholanolone were
determined in vitro using two comparing methods. As NSAIDs are very frequently used (not only)
by athletes, the inhibitory impact of indomethacin intake on the steroid metabolism was evaluated,
and steroid profile alterations were detected in vivo (one male and one female volunteer). Significant
differences between samples collected before, during or after the intake of indomethacin for selected
steroid profile markers were observed. The presented results are of relevance for the interpretation of
results from doping control analysis. Additionally, the administration of NSAIDs should be carefully
reconsidered due to their potential as endocrine disruptors.
Keywords: NSAID; inhibition; doping; aldo-keto reductases; endocrine disruption
1. Introduction
Anabolic androgenic steroids (AAS) are very frequently used drugs in sports [1]. Their use as
doping agents is prohibited in and out of competition by the World Anti-Doping Agency (WADA;
class S1 in the WADA prohibited list) [2]. The analytical detection is challenging, especially if so-called
pseudo endogenous AAS (e.g., exogenous testosterone) are used as performance enhancing substances,
due to their high similarity to the naturally occurring endogenous AAS (EAAS). To detect the misuse
of those pseudo endogenous and some synthetic AAS, anti-doping laboratories monitor in a first
step, concentrations and concentration ratios of selected EAAS according to the WADA technical
document TD2018EAAS in urine samples collected from the athletes [3]. In case of misuse of pseudo
endogenous AAS or some synthetic AAS, those steroid profile markers are altered and a confirmative
method using gas chromatography combustion isotope-ratio mass-spectrometry (GC-c-IRMS) is
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applied. Since it has been shown that ratios of urinary steroids are stable over months and even
years in adult humans [4–6] but show interindividual variations, the steroidal module of the Athlete
Biological Passport (ABP) was introduced by WADA in 2014 [7]. With this longitudinal monitoring
model, it is possible to better detect intraindividual changes, and hence the potential misuse of AAS.
However, it was shown that besides various endogenous and exogenous parameters, the intake of
selected (non-prohibited) drugs can influence the individual steroid profile and lead to suspicious
testing results [8–10]. To better understand how changes in the steroid profile can occur after the
intake of specific drugs, it is helpful to understand and further investigate the steroid metabolism
and potential points of interference. One enzyme-family which plays a key role in the metabolism
of EAAS are aldo-keto-reductases (AKR; Figure 1). In this study we focused on the AKR1C3, which
is known to oxidize 17-hydroxy steroids to their corresponding 17-oxo metabolites and vice versa.
It was reported that the reduction route is favored in vivo [11]. Furthermore, it was reported by Byrns
et al. that the non-steroidal anti-inflammatory drug (NSAID) indomethacin inhibits the AKR1C3
catalyzed reduction in androst-4-ene-3,17-dione in vitro selectively over the closely related AKR1C2
and AKR1C1 [12,13]. No further investigations have been made on the inhibitory effect of indomethacin
on 5β-androstanes metabolized by AKR1C3. As NSAIDs are very frequently used drugs (not only)
among athletes [14,15], this work aims to further investigate the influence of indomethacin on the
steroid metabolism in vitro and wants to show the relevance of indomethacin on the urinary steroid
profile in vivo. Hence, the work consists of an in vitro part and an in vivo application trial. The in vitro
experiments were analyzed spectro-fluorometrically in real time and by gas chromatography coupled
to a quadrupole-time-of-flight mass spectrometer (GC-QToF) as confirmative tests. For the in vivo
part, indomethacin was administered to one male and one female volunteer in therapeutic doses
over 14 days. Urine samples before, during and after the administration were collected and analyzed.
The results first give ideas on the impact of indomethacin intake on steroid profiles in doping control
analysis and its potential mechanism of endocrine disruption.
Figure 1. Metabolism of endogenous anabolic androgenic steroids (EAAS); blue and bold: substrates
and enzymes used in this publication.
2. Results
2.1. Qualitative Incubation In Vitro
With the applied GC-MS (gas chromatography-mass spectrometry) method, all EAAS of interest
were sufficiently separated (no interference between steroids was expected to occur simultaneously
during the different incubations). All analyzed EAAS standards are depicted in the upper chromatogram
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in Figure 2. For all background incubations (absence of enzyme) no other steroids besides the substrate
were detectable. The internal standard (17α-methyltestosterone; substance K in Figure 2) was detected
in all samples.
Figure 2 shows chromatograms of samples after enzymatic incubations in solid lines. As no
substrate was detected after the incubation of Etio (etiocholanolone, substance D in Figure 2) the sample
chromatogram (solid line) was superimposed by the chromatogram of the background-incubation
(dotted line). A detailed display of chromatograms of all performed incubations and background
samples is available as supplementary data (Supplement S1). Chromatograms are displayed as total
ion current chromatograms. Hence, peaks originating from the incubation media are also present.
This is assumed to be the case for the two big peaks at 8.79 min and at 9.47 min, as both are also
present in background-samples (without enzyme). They are hence neglected in the results presentation
and discussion.
In the following paragraph, detailed outcomes of individual steroid incubations with AKR1C3
(aldo-keto reductase 1C3) will be described. After incubation of 5αAD (5α-androstanedione, substance
G in Figure 2), small amounts of substrate were detected. In addition, minor amounts of 5αDHT
(5α-dihydrotestosterone, substance H in Figure 2) and larger amounts of And (androsterone, substance
C in Figure 2) and 5αAdiol (5α-androstane-3α,17β-diol, substance E in Figure 2) were detected. All of
these compounds have a 5α-androstane structure in common and are highlighted in orange in Figure 2.
After incubation of 5βAD (5β-androstanedione, substance A in Figure 2) no or small amounts of
substrate, but peaks corresponding to 5βAdiol (5β-androstane-3α,17β-diol, substance F in Figure 2)
and Etio (substance D in Figure 2), were detected. Furthermore, very minor amounts of 5βDHT
(5β-dihydrotestosterone, substance B in Figure 2) were detectable in one of two replicates (not visible
in Figure 2). All of these compounds have a 5β-androstane structure in common and are highlighted
in green in Figure 2.
After incubation of AED (androst-4-ene-3,17-dione, substance I in Figure 2) with AKR1C3, AED
itself and its metabolite T (testosterone, substance J in Figure 2) were detected. Both compounds are
highlighted in violet in Figure 2.
After incubation of And (substance C in Figure 2) with AKR1C3, peaks corresponding to And and
5αAdiol (substance E in Figure 2) were detected. Only minor amounts of the substrate were detected
(small peak at 8.36 min with framed retention time (RT) in androsterone chromatogram in Figure 2).
And and 5αAdiol share a 5α-androstane structure and are hence highlighted in orange in Figure 2.
After incubation of Etio (substance D in Figure 2) the substrate itself was detected in only one
of the two replicates (indicated as dotted peak at 8.41 min corresponding to Etio detected in the
background sample). The metabolite 5βAdiol (substance F in Figure 2) was present in both replicates.
As Etio and 5βAdiol share a 5β-androstane structure they are highlighted in green in Figure 2.
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Figure 2. Chromatogram of EAAS standards (upper chromatogram) and steroids detected in
overview-incubations (chromatograms below) analyzed on GC-MS with substrates of incubation
indicated in upper left corner of each chromatogram and highlighted by framed retention time (RT);
colored peaks corresponding to: A: 5βAD (RT: 7.83, 8.09 min, derivatization isomers); B: 5βDHT
(RT: 7.94; 8.19 min, derivatization isomers); C: And (RT: 8.36 min); D: Etio (RT: 8.40 min); E: 5αAdiol
(RT: 8.48 min); F: 5βAdiol (RT: 8.51 min); G: 5αAD (RT: 8.85 min); H: 5αDHT (RT: 8.93 min); I: AED
(RT: 8.99 min); J: T (RT: 9.07 min); K: MeT (RT: 9.39 min; internal standard); orange peaks indicate
5α-androstanes, green peaks indicate 5β-androstanes, violet peaks correspond to T and AED, MeT is
colored in black. Peaks not indicated with RT do not correspond to any EAAS standards.
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2.2. Km Determination In Vitro
Experiments to determine the Michaelis-Menten constant (Km) of AKR1C3 catalyzed Etio
metabolism were carried out in 96-well plates to detect real-time changes in fluorescence intensities.
The Km determined with the spectro-fluorometric method was 9.7 µM (standard error of the mean;
SE = 1.4 µM; Figure 3B). As previously described, analysis of terminated incubations was additionally
carried out using a GC-QToF instrument. The determined Km with this method was 15.8 µM
(SE = 0.9 µM; Figure 3A). Michaelis-Menten curves of both measurements are depicted in Figure 3.
Figure 3. Michaelis-Menten curve of Etio with AKR1C3 generated with data from GC-QToF data (A):
Km = 15.8 µM (SE = 0.9 µM) and spectro-fluorometric measurement (B): Km = 9.7 µM (SE = 1.4 µM).
2.3. IC50 Determination In Vitro
For the measurements performed with the spectro-fluorometric method, the half maximal
inhibitory constant (IC50) could not be calculated. Several background samples (enzyme substituted
by phosphate buffered saline (PBS) 0.1 M) showed higher initial velocities than the samples which
contained enzyme. Hence, a subtraction of background-velocities from initial velocities of samples
would have resulted in negative values and hence negative enzyme activities would have been
determined. Therefore, IC50 values were determined with the data obtained by GC-QToF analysis.
The IC50 determined using the mass-spectrometric method was successful and resulted in a value
of 4.8 µM (SE = 1.0 µM). The corresponding curve is depicted in Figure 4.
Figure 4. Inhibition curve generated from GC-QToF data: IC50 = 4.8 µM (SE = 1.0 µM).
Metabolites 2020, 10, 463 6 of 19
2.4. In Vivo Administration Trial
To illustrate all significant changes in the steroid profile markers of the male and the female
volunteers, boxplots of steroid profile markers where significant differences were found between at
least two groups are displayed in Figure 5.
Figure 5. Boxplots of steroid profile markers with significant differences between at least two groups.
(A–I): female volunteer; (J–M): male volunteer; * significant difference with p < 0.0167; ** very significant
difference with p < 0.0033; *** highly significant difference with p < 0.00033.
In the male volunteer, significant changes between at least two groups, i.e., before and during
administration, were detected for And (Figure 5J), And/T ratio (Figure 5K), And/Etio ratio (Figure 5M)
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and 5αAdiol/5βAdiol ratio (Figure 5L). The concentration of And decreased by 15% (difference in
median) during the administration of indomethacin compared to the concentration measured before
the administration and decreased by 21% (difference in mean) after the administration compared to
before the administration. The And/T ratio decreased by 11% during the administration compared to
the ratios before (difference in mean values). The And/Etio ratio increased by 5% (difference in mean)
after the administration compared to during administration and the 5αAdiol/5βAdiol ratio increased
by 9% (difference in mean) after administration compared to before administration. In the female
volunteer, significant differences were detectable for all examined steroid profile markers except for Etio
concentration and And/T ratio. Changes solely between the groups before and during administration
of indomethacin were detectable for T (Figure 5A), And (Figure 5C), 5αAdiol (Figure 5D) and 5βAdiol
(Figure 5E). Changes solely between the groups during and post administration were detectable for
E (epitestosterone, Figure 5B). Changes between the groups before/during and during/after were
detectable for T/E (Figure 5F), 5αAdiol/5βAdiol (Figure 5H) and 5αAdiol/E (Figure 5I) ratios. Changes
between the groups before/during and before/after were significant for And/Etio ratio (Figure 5G).
Furthermore, concentrations and concentration ratios of steroid profile markers, which showed
significant changes between at least two groups, were plotted over the whole sampling time. The first
sampling point was at t = 0 h. All curves are displayed in Figure 6. From this visualization it is observable
that in particular, the concentration of E and 5βAdiol and the T/E, 5αAdiol/E and 5αAdiol/5βAdiol
ratios in the female volunteer change a lot over time (Figure 6b,e,f,h and i). Additionally, for the
And/Etio ratio in the female volunteer (Figure 6g) and for the 5αAdiol/5βAdiol ratio in the male
volunteer (Figure 6l) an increase during the administration of indomethacin is clearly visible.
Indomethacin and its two evaluated metabolites were detected over the whole time of
administration. Thereby, the highest concentration of indomethacin was determined in the samples
collected after the administration of the drug (13 h). The two following samples before the next intake
(18 h and 22 h) were much lower than the detected peak-concentration. Samples collected after the
administration period (day 15 and later) contained, if at all, only trace amounts of indomethacin or its
examined metabolites (Figure 7).
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Figure 6. Time course of steroid profile markers which changed significantly over time; (a–i): female
volunteer; (j–m): male volunteer.
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Figure 7. Measured concentrations of indomethacin (blue squares) and its metabolites
O-desmethoxyindomethacin (orange circles) and N-deschlorobenzoylindomethacin (green triangles) in
urine samples collected from the male volunteer. Sampling points for one day were: 7 h, 13 h, 18 h
and 22 h.
3. Discussion
3.1. In Vitro Overview Incubation
Overview incubations were performed to examine the suitability of different endogenous steroids
as substrate for the subsequent inhibition experiments. Important requirements were:
• The substrate is an endogenous steroid, which plays a role in the steroid module of the Athlete
Biological Passport of the World Anti-Doping Agency;
• No side reaction is taking place besides the formation of the desired product;
• The initial velocity is fast enough to be monitored spectro-fluorometrically.
From those requirements it was assumed that a substrate which shows nearly complete formation of
product, with no formation of side products after 5.5 h would be an adequate candidate for the following
experiments. The requirement of no side reactions guarantees that a “one-to-one reaction” is taking
place. Therefore, NADPH (β-Nicotinamide-adenine-dinucleotide-phosphate) consumption measured
spectro-fluorometrically directly correlates with product formation measured on the GC-QToF, and the
data from spectro-fluorometric measurements and chromatographic confirmation are comparable.
The nearly complete formation of the product after a (rather long) incubation period of 5.5 h indicates a
higher reaction velocity which would result in a higher sensitivity of the spectro-fluorometric analysis.
For all enzymatic incubations, the formation of product(s) was observed. Hence, a negative effect
of methanol or acetonitrile (used as solvents for steroid substrates) on the outcome of the qualitative
experiments was not expected.
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Five endogenous steroids were chosen for preliminary experiments. 5α- and 5β-androstanedione
formed three products each, which was not expected, since all other examined EAAS only showed the
formation of one product. Following the pattern of all other observed products, we assumed that also
5α- and 5β-androstanedione would form their 17-hydroxy-metabolite, 5α- or 5β-dihydrotestosterone,
respectively. However, we only detected small amounts, of the latter and of the substrates, if any. Instead,
we observed the formation of And or Etio and 5αAdiol or 5βAdiol, respectively. Those findings are in
accordance with the literature, where AKR1C3 is described to act as 3α-hydroxysteroid dehydrogenase
(3αHSD) as well as 17βHSD [16]. Further investigations would be interesting to evaluate the complex
kinetics and the metabolite formation sequence to gain further insights into enzyme characteristics.
In the analyzed samples of AED, And and Etio, only one product was detected. Whereas AED
and And formed their corresponding product T and 5αAdiol in relatively small amounts in both
replicates, Etio was converted nearly completely into its product 5βAdiol in one of two replicates
(Figure 2). Due to the complete metabolization and the absence of any side reactions, Etio was chosen
as the substrate for the subsequent in vitro kinetic experiments.
3.2. Kinetic Measurements In Vitro
To prevent the potential interfering effects of acetonitrile or methanol (used as solvent of the
steroid substrate for qualitative incubations) with the enzyme, Etio was dissolved in DMSO (dimethyl
sulfoxide) for all the kinetic measurements. Constant volumes of DMSO and ethanol were added
to all incubations (with and without indomethacin and to samples without enzyme) to generate
comparable results.
To find the optimal substrate concentration for the subsequent inhibition experiments,
the Km value of the AKR1C3-catalyzed reduction in Etio is needed. These values were determined
experimentally since, to our knowledge, no kinetic data on the desired reaction are available in the
literature. The Km values from the spectro-fluorometric and mass spectrometric measurements
(Km(fluoro) = 9.7 µM, standard error of the mean; SE = 1.4 µM and Km(QToF-MS) = 15.8 µM
(SE = 0.9 µM) show that the method used to analyze the kinetic experiments has an impact on
the determined Km value. Despite the difference in the Km values determined with the two methods,
the examined reaction has an efficiency comparable to other steroid-reductions catalyzed by AKR1C3
reported in the literature [12,16]. The reactions of steroid substrates are relatively inefficient compared
to other substrates converted by AKR1C3, e.g., 9,10-phenanthrenequinone (Km = 1.5 ± 0.7 µM) [12,17].
This may explain why the spectro-fluorometric method showed good results for the Km determination,
but not for inhibition experiments. Initial velocities in the inhibition experiments were generally
lower than those determined in the Km experiments, resulting in lower sensitivities. The presence of
indomethacin may be another explanation for the unsuitability of the spectro-fluorometric method for
the inhibition experiment. In background reactions, we observed that large amounts of indomethacin
led to quenching of the fluorescence intensity generated by NADPH. Generally, subtracting the
background signal from the sample-signal should compensate for this difference. Nevertheless,
we observed that in particular, background samples with high amounts of indomethacin resulted
in higher initial velocities than the corresponding samples with the enzyme. As the evaluation of
those data would result in negative enzyme activities and in activities far above 100%, the applied
spectro-fluorometric method is not suitable to determine the IC50 value of the inhibition of AKR1C3
catalyzed reduction in Etio. Due to those difficulties in the spectro-fluorometric method, the IC50
was determined using mass spectrometry. The determined value of 4.8 µM (SE = 1.0 µM) was
transformed into an inhibition constant (KI) using the “IC50-to-KI-converter” [18]. Byrns et al. reported
a competitive inhibition type of indomethacin on the reduction in androstenedione by AKR1C3 [12].
Assuming that the inhibition of the AKR1C3 catalyzed reduction in Etio follows the same pattern,
the calculated KI would be 2.2 µM. This result is in accordance with findings from the literature, where
different substrates were used [12,19,20]. The determined KI lies on the upper range of the therapeutic
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blood-plasma/serum concentration of the drug (0.84–2.8 µM) [21], resulting in the hypothesis for the
in vivo experiments that therapeutic doses of indomethacin may lead to relevant inhibition of AKR1C3.
3.3. In Vivo Administration Trial
As AKR1C3 plays a crucial role in the metabolism of EAAS, used as markers in doping control
analysis, we assumed that the intake of therapeutic doses of indomethacin may lead to changes in the
steroidal profile. Since the aim of this study was getting a first idea on the detectability of changes
in the steroid profile after the intake of therapeutic doses of indomethacin over 14 days, only one
male and one female volunteer were included in the study. Despite this limited number of volunteers,
we are convinced that the presented results are relevant for the anti-doping community and other
fields where steroid quantification is of importance. As the knowledge of so-called confounding factors
is of paramount importance for the interpretation of steroid profiles [10], this study will be of value
for improved interpretation of steroid profiles. To enhance the exploration of factors influencing the
steroid profile, we want to share our findings to raise awareness and induce further in-depth research.
Statistical analysis of in vivo data showed significant changes between the groups (before, during
and after indomethacin administration) for several EAAS in both volunteers (Figures 5 and 6). While
in the male volunteer only four steroid profile markers changed significantly (A, And/T, And/Etio
and 5αAdiol/5βAdiol), nine of the 11 markers changed in the female volunteer. This is in accordance
with our previous study on the influence of ibuprofen intake on the steroid profile, where only a few
steroid profile markers were affected in the male volunteer, while the majority of markers changed
significantly in the female volunteer [22].
Due to the experimental setting, both individual and sexual differences may be explanations for
this effect. However, sexual differences seem to be reasonable as an explanation. As females have lower
concentrations of EAAS than males, their concentrations and concentration ratios monitored in the
steroid profile of the Athlete Biological Passport are much more affected by exogenous and endogenous
parameters (e.g., menstrual cycle, intake of contraceptives or emergency contraceptives, ethanol) [23,24].
Mullen et al. showed that the epitestosterone concentration changes significantly during the menstrual
cycle, and hence the T/E and 5αAdiol/E ratios are significantly affected. Similar observations are true
for the female volunteer in this study who did not take any oral contraceptives for at least six months
before and during the study. In particular, the concentration of E, the T/E and the 5αAdiol/E ratios
changed a lot over the whole collection time (Figure 6). The influence of physiological changes on
these parameters may need further investigation. In a publication by Mareck-Engelke et al. [25] also
considering the potential circadian rhythm and the menstrual cycle in females, the And/Etio ratio is
reported to be the most stable, but also the 5αAdiol/5βAdiol ratios showed a coefficient of variation
(CV) <30%. However, both ratios (A/Etio and 5αAdiol/5βAdiol) changed significantly in the female
volunteer during indomethacin application. In addition, the concentrations of And and 5αAdiol
increased significantly, while the concentration of 5βAdiol decreased significantly during the intake.
In the male volunteer, the picture is not as complex as in the female volunteer. The significant
decrease in And/T ratio may be explained by the decrease in And during the intake of indomethacin.
The 5αAdiol/5βAdiol ratio increased significantly during the intake of indomethacin, which is in
accordance with the observations from the female volunteer.
For both volunteers, several steroid profile markers changed significantly under the influence
of indomethacin but no criteria for a suspicious steroid profile during an anti-doping test were
met for a sequence of successive samples. Nonetheless, selected concentrations and concentration
ratios were significantly influenced by the intake of the drug. Additionally, the concentrations of
indomethacin and its metabolites O-desmethylindomethacin and N-deschlorobenzoylindometacin were
determined in the urine samples collected from the male volunteer to obtain some first information
on the long-time influence of indomethacin on the steroid profile. It was found that the highest
concentrations of indomethacin are detectable in the sample which was collected after the drug intake.
The samples collected after this and before the next indomethacin administration contained much
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lower concentrations (Figure 7). This is in accordance with the half-life of 3–11 h [21]. Based on the
half-life, and since indomethacin and its monitored metabolites are only detectable in urine samples
collected close to the intake of the drug, one would assume that no differences in steroid profile
markers are observable between samples collected before and after indomethacin intake. Nevertheless,
there are a few significant changes in the steroid profile detectable between samples collected before
and after the administration of indomethacin (Figure 5G,J,L). Other profile markers are affected
during the intake of the drug but show no significant difference between the groups during and after
indomethacin intake (Figure 5A,C–E,K). An explanation of these effects may be a prolonged influence
of indomethacin on AKR1C3 and thus also the steroidal profile. To further investigate the significance
for doping-control analysis and to reassess our hypothesis a study with a higher number of volunteers
is already in preparation.
In addition to the impact on results interpretation in anti-doping analysis, the presented results are
also relevant in evaluating potential endocrine disrupting substances (EDS). Like several other NSAIDs,
indomethacin has anti-inflammatory, anti-pyretic and analgesic effects. It inhibits the cyclooxygenase
and hence the formation of prostaglandins (PGs) which are responsible for the manifestation of pain,
inflammation and fever. The literature reports that many putative EDSs inhibit the PG synthesis [26].
Additionally, the literature also discusses the role of PG synthesis inhibition by indomethacin in the
mechanism of endocrine disruption [27,28]. However, it is accepted that probably not only the inhibition
of PG synthesis is involved. Previous studies showed that indomethacin interferes with the testosterone
production in various models [26,27,29–32]. Barkay et al. reported that plasma-testosterone levels in
oligospermic men decreased significantly after an intake of indomethacin (75 mg over 90 days) [30].
In comparison, Knuth et al. reported an investigation with an administration of a lower dose and
shorter duration (25 mg indomethacin per day over 14 days, i.e., similar to our administration).
No significant change was detectable in the serum testosterone concentration in young, healthy male
volunteers. This is in accordance with our presented findings, where no significant changes in the
urinary testosterone concentration were detectable in the male volunteer. In the female volunteer,
where steroid profile markers were showed to be more easily affected, significant changes in the
urinary testosterone concentrations were detectable during the intake of indomethacin compared
to pre-administration. Future investigations could hence investigate whether higher daily doses or
prolonged administrations of indomethacin would also affect testosterone levels in the male volunteer.
Additionally, studies on the impact of indomethacin on AKRs were published [12,19], and in vitro
experiments presented in our study showed the effect of indomethacin on the AKR1C3 catalyzed
reduction in Etio. All investigations commonly show that indomethacin inhibits AKR1C3 in vitro.
Among other catalyzed reactions, this enzyme plays a key role in the metabolism of androgens,
estrogens and progestagens [16]. As AKR1C3 is implicated in some hormone dependent malignancies
and endocrine disorders, drugs selectively inhibiting AKR1C3 are investigated to be used as cancer
treatment or drugs treating endocrine disorders for patients where this enzyme is overexpressed [33].
Our work demonstrates that the inhibition of AKR1C3 by indomethacin alters selected markers of
the urinary steroid profile in healthy volunteers. In the context of AKR1C3 involvement in androgen,
estrogen and progestin metabolism, an effect on estrogens may also be hypothesized. Based on our
study and on findings from the literature, the risk potential of indomethacin and its role as endocrine
disruptor should be reinvestigated.
4. Materials and Methods
4.1. Materials
Androst-4-ene-3,17-dione (AED), 17β-hydroxyandrost-4-en-3-one (testosterone; T),
17α-hydroxyandrost-4-en-3-one (epitestosterone; E), 3α-hydroxy-5α-androstan-17-one
(androsterone; And), 5α-androstane-3,17-dione (5α-androstanedione; 5αAD), 17β-hydroxy-5α-
androstan-3-one (5α-dihydrotestosterone; 5αDHT), 5α-androstane-3α,17β-diol (5αAdiol), 3α-hydroxy-
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5β-androstan-17-one (etiocholanolone; Etio), 5β-androstane-3,17-dione (5β-androstanedione; 5βAD),
17βhydroxy-5β-androstan-3-one (5β-dihydrotestosterone; 5βDHT), 5β-androstane-3α,17β-diol
(5βAdiol) and 17α-methyltestosterone (MeT; used as internal standard) were from Steraloids (Newport,
RI, USA), Sigma-Aldrich (Milano, Italy) or TCI (Eschborn, Germany). Deuterated standards T-d3,
E-d3, And-glucuronide-d4, Etio-d5, 5αAdiol-d3, 5βAdiol-d5 were obtained from the National
Measurement Institute (NMI, Lindfield, NSW, Australia). Indomethacin, O-desmethylindomethacin
and N-deschlorobenzoylindomethacin used as reference compounds for the excretion study were
all purchased from TRC (Toronto Research Chemicals, North York, ON, Canada). Probenecid as
internal standard was from Sigma Aldrich (Milan, Italy). Indomethacin, used as inhibitor for in vitro
experiments, was of European Pharmacopoeia (Ph. Eur.) quality and purchased from Sigma-Aldrich
(Steinheim, Germany). For the in vitro assay, solutions of different concentrations of the substrate
Etio (20 µM, 100 µM, 200 µM, 400 µM, 1 mM, 2 mM) and the inhibitor indomethacin (6 µM, 20 µM,
60 µM, 200 µM, 600 µM, 2 mM) were prepared from stock solution by dilution of the solid substance in
DMSO in the case of Etio and in ethanol in the case of indomethacin. Solvents (ethanol, acetonitrile,
DMSO, tert-butyl methyl ether (TBME), methanol or ethyl acetate) and reagents (sodium phosphate
and sodium hydrogen phosphate, potassium carbonate and sodium hydrogen carbonate, acetic acid
and sodium acetate) were of analytical, high performance liquid chromatography (HPLC) or of
high performance liquid chromatography-mass spectrometry (HPLC-MS) reagent grade and were
purchased from Merck (Darmstadt, Germany), Carl Roth (Karlsruhe, Germany), Honeywell Fluka
(Milan, Italy) or Sigma Aldrich (Milan, Italy). NADPH regenerating system solution A and solution B
were used for the overview incubations and were purchased from Corning Gentest (Woburn, MA,
USA). The cofactor for the enzymatic incubations to determine the kinetic values Km and IC50 was
NADPH-tetra-sodium salt (NADPH-Na4) and was purchased from Carl Roth (Karlsruhe, Germany).
The human recombinant enzyme AKR1C3 (expressed in Escherichia coli (E. coli, catalogue number:
NBC1-21051) originated from Novus Biologicals Europe (Abingdon, United Kingdom). Phosphate
buffered saline (PBS, 0.5 M, pH 7.4) from Corning Gentest (Woburn MA, USA) was diluted and
used for all in vitro experiments. The preparation of β-glucuronidase from E. coli was from Roche
Diagnostic (Mannheim, Germany). N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) was
supplied by Chemische Fabrik Karl Bucher GmbH (Waldstetten, Germany), ammonium iodide
(NH4I), mercaptoethanol and ethanthiol were from Sigma Aldrich (Milano, Italy or Taufkirchen,
Germany). Water was obtained from a “MilliQ” (Millipore S.p.A., Milano, Italy) or from “SG LaboStar”
(Guenzburg, Germany) water purification system.
4.2. In Vitro Qualitative Incubation
Incubations were performed in duplicate in parallel to a background sample where the volume of
enzyme was substituted by PBS 0.1 M. NADPH regenerating system (consisting of 1.3 mM NADP+,
3.3 mM glucose-6-phosphate and 3.3 mM magnesium chloride and 0.4 U/mL glucose-6-phosphate
dehydrogenase in final assay), AKR1C3 (0.64 µM in final assay) and PBS 0.1 M were added to a 1.5 mL
reaction tube, centrifuged briefly and prewarmed at 37 ◦C for 5 min. AED, And, 5αAD, 5βAD or
Etio (dissolved in methanol or acetonitrile; concentration in stock solution 1 mg/mL) were added as
substrates (final concentration in assay: steroid ~50 µM, solvent 1.5% (v/v)). After brief centrifugation,
incubation was carried out for 5.5 h at 37 ◦C. Incubation was terminated by the addition of 200 µL cold
acetonitrile and samples were extracted immediately or stored at −20 ◦C until extraction.
4.3. In Vitro Kinetic Assay
All incubations were performed in triplicate. The incubations were carried out in 96-well plates
(black, flat black bottom, Sarstedt, Nümbrecht, Germany) and analyzed spectro-fluorometrically in
real-time. After incubation, the entire assay-volume was transferred to a 0.5 mL reaction tube and
200 µL of cold acetonitrile were added to denature the enzyme and thereby end the reaction. Samples
were stored at −20 ◦C until confirmative GC-QToF analysis was performed. For each experiment
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NADPH solution (in PBS 0.1 M) was prepared freshly. Ethanol or indomethacin dissolved in ethanol,
NADPH (12 µM in final assay) in PBS 0.1 M, AKR 1C3 (1.03 µM in final assay) and PBS 0.1 M were added
to the appropriate location on the well-plate. The mixture was prewarmed for 3 min at 37 ◦C under
agitation. After the addition of Etio, the plate was centrifuged briefly, and incubation was performed
for 1000 s in the plate reader. Concentrations of Etio for Michaelis-Menten-constant (Km)-determination
were 1 µM, 5 µM, 10 µM, 20 µM, 50 µM or 100 µM in the final assay. In experiments to evaluate
the half maximal inhibitory concentration (IC50), Etio was used in a concentration slightly below the
determined Km (7 µM in final assay) throughout. Indomethacin (dissolved in ethanol) was added,
resulting in concentrations of 0.1 µM, 0.3 µM, 1 µM, 3 µM, 10 µM, 30 µM or 100 µM in final assay.
4.4. Administration Study
Two healthy volunteers, one male and one female (additional information on volunteers in Table 1),
were treated with indomethacin (Indoxen 25 mg; Recordati S.p.A.; Milan, Italy) for 14 days. Urine
samples were collected 4 times per day for five days prior to the treatment and the whole treatment
phase (sampling points: 07:00 h; 13:00 h, 18:00 h and 22:00 h) and one time per day after the treatment
phase (sampling point 13:00 h over 11 days for male volunteer and 8 days for female volunteer). Urine
samples were anonymized and stored in sterile plastic tubes at −20 ◦C until analysis. The study was
approved by the “Comitato Etico Lazio 1” with the reference number: 1553/CE Lazio 1. All volunteers
gave informed consent.
Table 1. Additional information on male and female volunteer included in this study.
Male Volunteer Female Volunteer
Age 29 30
Weight 63 kg 60 kg
Hight 172 cm 178 cm
BMI 21.3 kg/m2 18.9 kg/m2
Dietary habits Normal diet (no restriction) Normal diet (no restriction)
Training Three times/week (swim and run) No
Oral contraceptive Ø No
4.5. Sample Preparation before Chromatographic Analysis
In case of in vitro samples (overview incubations and kinetic experiments), MeT (in methanol;
10 µL of 1 g/L-solution for overview study or 10 µL of 0.1 g/L-solution for kinetic study) was added.
Samples were centrifuged (at 9660× g) to sediment the denatured enzyme. Supernatant was transferred
to fresh glass-tubes and 1 mL PBS 0.1 M and 5 mL TBME (in case of kinetic experiments) or 2 mL ethyl
acetate (in case of the overview incubations) were added.
For all urine samples, specific gravity was determined, to normalize steroid and NSAID
concentrations according to the WADA technical document TD2018EAAS, using a digital refractometer
RM40 (Mettler Toledo, Novate Milanese, Italy) [3]. Steroids (free and glucuronide fraction) were
extracted using an already established protocol for steroid profiling of endogenous steroids, which
is used routinely in the Italian anti-doping laboratory, Rome [34–36]. In brief, 2 mL of urine, 30 µL
of β-glucuronidase, 750 µL of 0.8 M PBS and 50 µL of internal standard (T-d3: 100 ng/mL, E-d3:
25 ng/mL, And-d4 glucuronide: 200 ng/mL, Etio-d5: 200 ng/mL, 5αAdiol-d3: 50 ng/mL, 5βAdiol-d5:
50 ng/mL, MeT: 250 ng/mL) were mixed and heated for 1 h at 55 ◦C. After hydrolysis, 500 µL of
carbonate/bicarbonate buffer (20% (w/v), pH 9) and 5 mL TBME were added.
For the extraction of indomethacin and its metabolites, 1 mL of urine, 50 µL probenecid (1 µg/mL)
as internal standard, 30 µL of β-glucuronidase and 500 µL PBS 0.8 M were added and hydrolysis was
achieved after 1 h of incubation at 55 ◦C. Before extraction, 500 µL sodium acetate buffer (pH 5) and
5 mL TBME were added.
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For in vitro and urine samples, liquid-liquid extraction was performed during agitation on
an automated shaker. Samples were centrifuged briefly (relative centrifugal force was 1008× g) to
separate the phases. The organic layer was transferred to new glass tubes after 5 min freezing in
an ethanol bath (−25 ◦C) or overnight at −20 ◦C in the freezer. The solvent was evaporated under
nitrogen at elevated temperatures and derivatization was performed at 75 ◦C for 30 min with 50 µL
MSTFA/mercaptoethanol/NH4I (1000:6:4 v/v/w; in case of in vitro kinetic samples and urine samples)
or MSTFA/ethanthiol/NH4I (1000:3:2 v/v/w; for overview incubations).
4.6. Fluorometric Analysis
Spectro-fluorometric measurements to determine the kinetic values of the enzymatic reaction
were carried out on a Safire II microplate reader (Tecan, Männedorf, Switzerland) in top-read mode.
Excitation wavelength was 340 nm, emission wavelength was 450 nm with both bandwidths set to
5 nm. For all experiments, gain was 120 and Z-position was 10,300 µm. Time between move and flash
was 10 ms, integration time 40 µs and 0 µs lag time. In the beginning of all experiments performed on
the plate reader, a calibration with 8 different concentrations of NADPH in PBS 0.1 M was performed.
For each concentration, 200 µL of NADPH solution were pipetted to 10 individual wells and each well
was measured with the same method used for kinetic experiments. The resulting calibration curve
was tested for linearity (Mandel-test, p = 99%), homogeneity of variances following DIN 38 402 A51
(p = 99%, including Grubbs outlier-test) and limit of quantification (LOQ) was determined following
DIN 32 645 (p = 95%, confidence level: 95%).
4.7. GC-MS Analysis
Samples originating from overview incubations were analyzed on an Agilent 7890A GC-System
coupled to an Agilent 5975C MSD (Agilent Technologies, Santa Clara, CA, USA). Injection volume was
2 µL with split injection in a ratio of 1:10. Injection temperature was set to 300 ◦C. Chromatographic
separation was achieved on an Agilent HP1 column (length: 17 m; diameter: 0.2 mm; film-thickness:
0.11 µm) with helium as carrier gas and a flow-rate of 1 mL/min. Oven program started at 193 ◦C
with 3 ◦C/min heating rate to 215 ◦C followed by a ramp with 40 ◦C/min to 310 ◦C and hold for 1 min.
Ionization was electron ionization (EI) and analysis was performed in scan mode with acquisition from
m/z 40 to m/z 750.
4.8. GC-QToF Analysis
Instrumental analysis of kinetic in vitro samples was performed on an Agilent GC-QToF 7890B/7200
(Agilent Technologies, Milano, Italy), equipped with an Agilent HP1 column (length: 17 m; diameter:
0.2 mm; film-thickness: 0.11 µm) with helium as carrier gas and a flow of 0.8 mL/min. Injection was
performed in split mode with a 1:10 ratio at 280 ◦C. The oven program had the following heating
rates: 188 ◦C hold for 2.5 min, 3 ◦C/min to 211 ◦C and hold for 2 min, 10 ◦C/min to 238 ◦C, 40 ◦C/min
to 320 ◦C and hold for 3.2 min. The coupled QToF was operated in full scan with an EI source and
ionization energy of 70 eV. Ions were detected from m/z 50 to m/z 750.
Calibration was performed with 9 different concentrations of 5βAdiol with fixed concentrations
of MeT. Each calibration level was measured twice. Calibration was tested for linearity applying the
Mandel Test, tested for outliers (no residuals >3 standard deviations) and weighted with a factor 1/x.
A signal to noise ratio of 10 to 1 was regarded as LOQ. Samples with signals below the LOQ were
regarded as not containing any analyte.
4.9. GC-MS/MS Analysis
For urinary steroid profile analyses, a previously described method was used [34–36]. It is validated
and currently used in routine analysis for the detection and quantification of pseudo-endogenous
steroids in the Italian anti-doping laboratory in Rome and accredited under ISO17025. In brief, analyses
were performed on an Agilent GC-MS/MS 7890 A/7000 (Agilent Technologies, Milano, Italy) equipped
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with an Agilent HP1 column (length: 17 m; diameter: 0.2 mm; film-thickness: 0.11 µm). The carrier gas
was helium with a flow rate of 1 mL/min, and the injection and transfer line temperature were set to
280 ◦C and injection was performed in split mode with a ratio of 1:20. The oven program was as follows:
180 ◦C hold for 4.5 min, 3 ◦C/min to 230 ◦C, 20 ◦C/min to 290 ◦C and 30 ◦C/min to 320 ◦C. Ionization
was achieved by EI and ionization energy was 70 eV. Analyses were performed in multiple-reaction
monitoring mode (MRM mode) with transitions used in the reference method. Quantitation of the
urinary steroids was based on the peak area ratio of the analyte to the corresponding internal standard.
Calibration and quality control samples were prepared in synthetic urine according to previously
published methods [37].
For quantification of indomethacin and its metabolites, a similar method was used. Aberrantly,
the oven program was 85 ◦C initial temperature hold for 1 min, 15 ◦C/min to 320 ◦C. Transitions for
analyzed compounds are listed in Table 2. Selectivity, linearity, repeatability, recovery and limit of
detection (LOD) were tested for the evaluation of method suitability (data not shown).
Table 2. Transitions for GC-MS/MS analysis of indomethacin and its metabolites
O-desmethylindomethacin and N-deschlorobenzoylindomethacin and the internal standard probenecid.
Analyte Precursor Ion [m/z] Product Ion [m/z] Collision Energy [eV]
Indomethacin (mono-TMS) 429 139; 246; 312 30; 30; 30
O-desmethylindomethacin (bis-TMS) 487; 304 139; 216; 232 30; 30; 30
N-deschlorobenzoylindomethacin (bis-TMS) 363; 348; 246 246; 320; 174 30; 10; 30
Probenecid (mono-TMS) 178; 342 104; 268 20; 20
4.10. Data Analysis of Kinetic Values
To determine the Michalis-Menten constant, initial velocities of the enzymatic reactions were
plotted against the concentration of Etio. Nonlinear regression was applied to the data using
OriginPro, Version 2019 (OriginLab Corporation, Northhampton, MA, USA). For spectro-fluorometric
measurements, the loss in fluorescence intensity over time curves were transformed in loss of
NADPH-concentration over time using a calibration curve. By applying linear regression to those
concentration-time curves, the initial velocity was determined. Initial velocities for the individual
samples were corrected with the background velocities. For mass spectrometric data the determined
concentration of formed product (5βAdiol) over time of incubation was regarded as initial velocity.
As no product was present in background incubations, no correction of this value was performed.
GC-QToF data were analyzed using Agilent MassHunter Workstation Quantitative Analysis for TOF
(Version 10.1; Agilent Technologies, Santa Clara, CA, USA).
To determine the IC50 values of the inhibition experiments, activity of the enzyme was plotted
against logarithmic concentrations of the inhibitor indomethacin in the assay. The activity of the
enzyme was calculated as a quotient of the initial velocities of the sample and the initial velocities
of the positive control (no inhibitor added). Nonlinear regression was performed using OriginPro,
Version 2019.
4.11. Data Analysis of Steroid Profiling and Indomethacin Detection in Urine Samples
Measured concentrations of EAAS, indomethacin and its metabolites were normalized for the
specific gravity of the sample according to the WADA technical document TD2018EAAS [3]. Samples
with a specific gravity at or below 1.001 were excluded from the analysis. For samples in which selected
analytes had concentrations below the limit of quantification (LOQ), the analyte in question and its
related ratios were excluded from analysis.
For the steroid-profiling samples of each volunteer were divided into three groups: before
treatment with indomethacin (n = 20) during the administration (n = 56 for male volunteer; n = 55 for
female volunteer due to exclusion of one sample where specific gravity was 1.001 and n = 54 for female
volunteer for E, T/E, 5αAdiol/E because concentration of E was below LOQ in this sample) and after
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indomethacin intake (n = 11 for male volunteer and n = 8 for female volunteer). The data were regarded
as independent from each other. All measured concentrations belonging to one group (per volunteer,
per substance, and phase during treatment) were tested for normal distribution (Shapiro Wilk test,
α = 0.05). In case of normal distribution the homogeneity of variances between the groups was also
tested (F-Test, α = 0.05). If the hypothesis of normal distribution was not rejected for both groups
examined, a two-sided parametric significance test for independent samples was applied. In case of
homogeneity of variances between groups, a two-sided t-test for independent groups was applied.
In case of rejection of homogeneity of variances between groups, Welch-Test was used. When for at least
one of the two examined groups the null-hypothesis of normal distribution had to be rejected, the less
powerful non-parametric Mann-Whitney U-Test was applied. For all significance tests (parametric and
non-parametric) the significance level was α = 0.0167 to deal with multiplicity problems of statistical
tests [38].
Normalized concentrations of indomethacin and its metabolites were plotted against the time
after first dose of indomethacin was administered.
5. Conclusions
The presented work shows the complexity of steroid metabolism in vitro and in vivo.
It furthermore reveals the advantages and drawbacks of different analysis methods for in vitro
enzymatic assays. A combination of in vitro and in vivo experiments was performed showing the
interference of the non-steroidal anti-inflammatory drug indomethacin with androgen metabolism and
the effect of indomethacin on the urinary steroid profile. The study provides results which can help to
interpret steroid profiles in anti-doping analysis. The presented results may also be relevant for other
fields of forensic or clinical toxicology and for the investigation of endocrine disrupting substances
(EDS). Future investigations on long-term effects or the influence of higher doses of indomethacin may
extend our findings.
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